Neoantigen DNA vaccine: Clinical Trials

5 trials of Neoantigen DNA vaccine, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 completed, 1 no longer available, 1 terminated. 2 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 12Completed 1, Terminated 1
Phase 22Active not recruiting 1, Withdrawn 1

Follow Neoantigen DNA vaccine: new trials by email Literature Review of Neoantigen DNA vaccine trials Research Report on Neoantigen DNA vaccine

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer
Neoantigen DNA vaccine, Durvalumab, TDS-IM v2.0 Device - Extensive-stage Small Cell Lung Cancer
Phase 2Active not recruitingWashington University School of Medicine62022-03-302025-10-22
PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma
Durvalumab, Tremelimumab, TDS-IM v1.0 System - Renal Cell Carcinoma
Phase 2WithdrawnWashington University School of Medicine2020-08-312020-08-13
Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy
Durvalumab, Neoantigen DNA vaccine, TDS-IM system (Inchor Medical Systems) - Triple Negative Breast Cancer, Triple Negative Breast Neoplasms
Phase 1TerminatedWashington University School of Medicine182019-07-232024-05-28
Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer
PROSTVAC-V, PROSTVAC-F, Nivolumab - Metastatic Hormone-Sensitive Prostate Cancer
Phase 1CompletedWashington University School of Medicine192018-09-142022-08-05
Expanded Access Neoantigen Vaccine in Solid Tumors
Neoantigen DNA Vaccine, Integrated electroporation device - Solid Tumor, Adult
No longer availableWashington University School of Medicine2024-03-12

Conditions studied

Carcinoma, Renal Cell (1)  ·  Small Cell Lung Carcinoma (1)  ·  Triple Negative Breast Neoplasms (1)

Sponsors

Washington University School of Medicine (5)

Countries

United States (4)

Top investigators

James J Hsieh, M.D., Ph.D. (1)  ·  Jeffrey Ward, M.D., Ph.D. (1)  ·  Russell Pachynski, M.D. (1)  ·  William E Gillanders, M.D. (1)  ·  William Gillanders, M.D. (1)

NIH funding

R01CA240983 (1)